Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September ...
As the management landscape of primary biliary cholangitis (PBC) changes, new second-line options offer effective alternatives for patients who respond inadequately to standard first-line treatment ...
PARIS, FRANCE, 7 May 2025 Today, Ipsen (Euronext: IPN; ADR: IPSEY) announced new data from two late-breaking presentations on IQIRVO® (elafibranor) during the European Association for the Study of the ...
Primary biliary cholangitis (PBC), previously referred to as primary biliary cirrhosis, is an autoimmune disorder characterized by intrahepatic cholestasis. While the precise etiology and pathogenesis ...
Please provide your email address to receive an email when new articles are posted on . Results presented at The Liver Meeting demonstrated volixibat (Mirum Pharmaceuticals) significantly improved ...
Primary biliary cholangitis (PBC) can deliver a significant blow to patients' quality of life, especially if they are not appropriately diagnosed and treated. "PBC is one of those liver diseases where ...
PARIS, FRANCE, 15 November 2024 Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data for Iqirvo ® (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results